Abstract
Mitochondrial biogenesis (MB) is the essential mechanism by which cells control the number of mitochondria. Cells respond to different physiologic, metabolic, and pathologic changes by regulating this organelle with high morphological and functional adaptability. A considerable number of proteins, transcription factors, upstream regulatory proteins and secondary mechanisms are involved in MB and the stabilization of new mitochondrial DNA. These MB activators and regulators, including the main participating proteins (e.g. PGC-1α and mtTFA), are candidates for therapeutic intervention in diverse diseases, like neurodegenerative disorders, metabolic syndrome, sarcopenia, cardiac pathophysiology and physiological processes like aging. In this review, we analyze the implication of MB in several diseases in which the MB pathway is affected. Furthermore, we describe therapeutical interventions on MB targets to boost MB for the prevention and treatment of human diseases. Furthermore, evidence based results and the knowledge gained during last years for some of these drugs aim us hypothesize about the value of a given treatment involved in the activation of MB.
Keywords: Aging, sarcopenia, metabolic syndrome, renal diseases, cardiac diseases, neurodegenerative diseases.
Current Pharmaceutical Design
Title:Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Volume: 20 Issue: 35
Author(s): Fabian Sanchis-Gomar, Jose Luis Garcia-Gimenez, Mari Carmen Gomez-Cabrera and Federico V. Pallardo
Affiliation:
Keywords: Aging, sarcopenia, metabolic syndrome, renal diseases, cardiac diseases, neurodegenerative diseases.
Abstract: Mitochondrial biogenesis (MB) is the essential mechanism by which cells control the number of mitochondria. Cells respond to different physiologic, metabolic, and pathologic changes by regulating this organelle with high morphological and functional adaptability. A considerable number of proteins, transcription factors, upstream regulatory proteins and secondary mechanisms are involved in MB and the stabilization of new mitochondrial DNA. These MB activators and regulators, including the main participating proteins (e.g. PGC-1α and mtTFA), are candidates for therapeutic intervention in diverse diseases, like neurodegenerative disorders, metabolic syndrome, sarcopenia, cardiac pathophysiology and physiological processes like aging. In this review, we analyze the implication of MB in several diseases in which the MB pathway is affected. Furthermore, we describe therapeutical interventions on MB targets to boost MB for the prevention and treatment of human diseases. Furthermore, evidence based results and the knowledge gained during last years for some of these drugs aim us hypothesize about the value of a given treatment involved in the activation of MB.
Export Options
About this article
Cite this article as:
Sanchis-Gomar Fabian, Garcia-Gimenez Luis Jose, Gomez-Cabrera Carmen Mari and Pallardo V. Federico, Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches, Current Pharmaceutical Design 2014; 20 (35) . https://dx.doi.org/10.2174/1381612820666140306095106
DOI https://dx.doi.org/10.2174/1381612820666140306095106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Controlled Release of Growth Factors for Regenerative Medicine
Current Pharmaceutical Design Congenital Disorders of Glycosylation (CDG): Update and Perspectives
Current Pediatric Reviews Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Ivabradine: A Current Overview
Current Clinical Pharmacology Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Targeting Antibody-Mediated Rejection in the Setting of ABOIncompatible Infant Heart Transplantation: Graft Accommodation vs. B Cell Tolerance
Current Drug Targets - Cardiovascular & Hematological Disorders Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews High Fidelity SNP Genotyping Using Sequence-Specific Primer Elongation and Fluorescence Correlation Spectroscopy
Current Pharmaceutical Biotechnology Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives
Current Diabetes Reviews Anticoagulation in Patients with Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondria-Targeted Drugs
Current Molecular Pharmacology Studying the Ethno-Pharmacological Basis of Antiepileptic Activity of Medhya Rasayanas- A Nootropic Package From Ayurveda
Current Traditional Medicine Xanthine Oxidase Inhibitors the Unappreciated Treatment for Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets